Related Experiment Video
Updated: Aug 28, 2025

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
Expression of nectin-4 in papillary renal cell carcinoma
Stefanie Zschäbitz1, Marie Mikuteit2,3, Christine Stöhr4
1Dept. of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, 69120, Heidelberg, Germany.
Background:
Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf (EV) is an antibody drug conjugate that targets Nectin-4. The aim of our study was to investigate the expression of Nectin-4 in a large cohort of papillary RCC specimens.
Patients And Methods:
Specimens were derived from the PANZAR consortium (Erlangen, Heidelberg, Herne, Homburg, Mainz, Mannheim, Marburg, Muenster, LMU Munich, TU Munich, and Regensburg). Clinical data and tissue samples from n = 190 and n = 107 patients with type 1 and 2 pRCC, respectively, were available. Expression of Nectin-4 was determined by immunohistochemistry (IHC).
Results:
In total, Nectin-4 staining was moderately or strongly positive in of 92 (48.4%) of type 1 and 39 (36.4%) type 2 of pRCC cases. No associations between Nectin-4 expression and age at diagnosis, gender, grading, and TNM stage was found. 5 year overall survival rate was not statistically different in patients with Nectin-4 negative versus Nectin-4 positive tumors for the overall cohort and the pRCC type 2 subgroup, but higher in patient with Nectin-4 positive pRCC type 1 tumors compared to Nectin-4 negative tumors (81.3% vs. 67.8%, p = 0.042).
Conclusion:
Nectin-4 could not be confirmed as a prognostic marker in pRCC in general. Due to its high abundance on pRCC specimens Nectin-4 is an interesting target for therapeutical approaches e.g. with EV. Clinical trials are warranted to elucidate its role in the pRCC treatment landscape.
Insights
Nectin-4 is frequently expressed in papillary renal cell carcinoma (pRCC), particularly type 1. While not a general prognostic marker, its abundance suggests Nectin-4 is a promising therapeutic target for pRCC.
Area of Science:
- Oncology
- Uro-oncology
- Molecular Pathology
Background:
- Nectin-4 promotes tumor growth and vascularization, making it a key target in cancer therapy.
- Current treatments for renal cell carcinoma (RCC) include tyrosine kinase inhibitors and checkpoint inhibitors.
- Enfortumab vedotin-ejf (EV) is an antibody-drug conjugate targeting Nectin-4.
Purpose of the Study:
- To investigate the expression levels of Nectin-4 in a large cohort of papillary renal cell carcinoma (pRCC) specimens.
- To assess the potential of Nectin-4 as a prognostic marker and therapeutic target in pRCC.
Main Methods:
- Analysis of tissue samples from 190 patients with pRCC type 1 and 107 patients with pRCC type 2.
- Immunohistochemistry (IHC) was used to determine Nectin-4 expression.
- Clinical data including age, gender, grading, TNM stage, and survival rates were analyzed.
Main Results:
- Nectin-4 was moderately or strongly positive in 48.4% of type 1 pRCC and 36.4% of type 2 pRCC.
- No significant association was found between Nectin-4 expression and clinicopathological factors (age, gender, grade, stage).
- Five-year overall survival was higher in Nectin-4 positive type 1 pRCC compared to negative cases (81.3% vs. 67.8%, p=0.042).
Conclusions:
- Nectin-4 expression is common in pRCC, especially type 1, but does not serve as a general prognostic marker.
- High Nectin-4 abundance on pRCC specimens identifies it as a potential therapeutic target, for example, with Enfortumab vedotin-ejf.
- Further clinical trials are necessary to confirm the role of Nectin-4 in pRCC treatment strategies.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Abnormal Proliferation
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...